Molecular design of two sterol 14α-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole

SummarySterol 14α-demethylase (CYP51) is one of the known major targets for azole antifungals. Therapeutic side effects of these antifungals are based on interactions of the azoles with the human analogue enzyme. This study describes for the first time a comparison of a human CYP51 (HU-CYP51) homology model with a homology model of the fungal CYP51 of Candida albicans (CA-CYP51). Both models are constructed by using the crystal structure of Mycobacterium tuberculosis MT-CYP51 (PDB code: 1EA1).The binding mode of the azole ketoconazole is investigated in molecular dynamics simulations with the GROMACS force field. The usage of special parameters for the iron azole complex binding is necessary to obtain the correct complex geometry in the active site of the enzyme models. Based on the dynamics simulations it is possible to explain the enantioselectivity of the human enzyme and also to predict the binding mode of the isomers of ketoconazole in the active site of the fungal model.

[1]  T J Walsh,et al.  Antifungal agents: chemotherapeutic targets and immunologic strategies , 1996, Antimicrobial agents and chemotherapy.

[2]  Hans W. Horn,et al.  ELECTRONIC STRUCTURE CALCULATIONS ON WORKSTATION COMPUTERS: THE PROGRAM SYSTEM TURBOMOLE , 1989 .

[3]  R. Fromtling.  Overview of medically important antifungal azole derivatives , 1988, Clinical Microbiology Reviews.

[4]  Wannian Zhang,et al.  A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. , 2000, Journal of medicinal chemistry.

[5]  A. Becke,et al.  Density-functional exchange-energy approximation with correct asymptotic behavior. , 1988, Physical review. A, General physics.

[6]  M. Botta,et al.  Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies. , 2002, Journal of medicinal chemistry.

[7]  A. Lapucci,et al.  Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. , 2002, Journal of medicinal chemistry.

[8]  A. Hofacre,et al.  Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF. , 2001, Journal of molecular biology.

[9]  M H Tarbit,et al.  Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives. , 1999, Journal of enzyme inhibition.

[10]  Min Zhang,et al.  Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. , 2003, Journal of medicinal chemistry.

[11]  Walter Thiel,et al.  Theoretical study of the vibrational spectra of the transition metal carbonyls M(CO)6 [M=Cr, Mo, W], M(CO)5 [M=Fe, Ru, Os], and M(CO)4 [M=Ni, Pd, Pt] , 1995 .

[12]  Guy H. Grant,et al.  Modeling cytochrome P450 14α demethylase (Candida albicans) from P450cam , 1994 .

[13]  S. Horvat,et al.  Characterization of the mouse lanosterol 14alpha-demethylase (CYP51), a new member of the evolutionarily most conserved cytochrome P450 family. , 2000, Archives of biochemistry and biophysics.

[14]  R. Ahlrichs,et al.  Efficient molecular numerical integration schemes , 1995 .

[15]  M. Botta,et al.  Chiral azole derivatives. 4. Enantiomers of bifonazole and related antifungal agents: synthesis, configuration assignment, and biological evaluation. , 2000, The Journal of organic chemistry.

[16]  D. Kelly,et al.  Characteristics of the heterologously expressed human lanosterol 14α‐demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents , 1999, Yeast.

[17]  D. Kelly,et al.  Generation of a complete, soluble, and catalytically active sterol 14 alpha-demethylase-reductase complex. , 1999, Biochemistry.

[18]  T. Poulos,et al.  Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Shaik,et al.  A theoretical study of electronic factors affecting hydroxylation by model ferryl complexes of cytochrome P-450 and horseradish peroxidase , 1999 .

[20]  D. Sheehan,et al.  Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.

[21]  C. Fattorusso,et al.  Construction of a model of the Candida albicans lanosterol 14-alpha-demethylase active site using the homology modelling technique. , 1998, Pharmaceutica acta Helvetiae.

[22]  Stahl Gr,et al.  Development of models for cytochrome P450 2A5 as well as two of its mutants. , 2005 .

[23]  D. Swinney,et al.  Stereoisomers of ketoconazole: preparation and biological activity. , 1992, Journal of medicinal chemistry.

[24]  Sudhir A. Kulkarni,et al.  Modeling and interactions of Aspergillus fumigatus lanosterol 14-alpha demethylase 'A' with azole antifungals. , 2004, Bioorganic & medicinal chemistry.

[25]  J. Dawson,et al.  Heme-Containing Oxygenases. , 1996, Chemical reviews.

[26]  D. Kelly,et al.  Differential inhibition of human CYP3A4 and Candida albicans CYP51 with azole antifungal agents. , 2000, Chemico-biological interactions.

[27]  S. Kelly,et al.  Molecular basis of resistance to azole antifungals. , 2002, Trends in molecular medicine.

[28]  Parr,et al.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.